Median effective dose of esketamine combined with remimazolam used in painless hysteroscopic day surgery for adults

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200057106

Enrollment

Unknown

Registered

2022-02-28

Start date

2022-03-01

Completion date

Unknown

Last updated

2023-10-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Painless hysteroscopic

Interventions

Experimental group 1:Esketamine

Experimental group 2:Remimazolam

Eligibility

Sex/Gender

Female

Age

18 Years to 64 Years

Inclusion criteria

Inclusion criteria: 1. Patients aged 18-65 years; 2. BMI 18-28 kg/m2; 3. Patients with ASA grade I-II; 4. The subjects understood and signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with respiratory and circulatory dysfunction; 2. Patients with hepatic and renal dysfunction; 3. The patient is allergic to esketamine or remimazolam; 4. Recently used sedative and analgesic drugs; 5. People with neuropsychiatric diseases.

Design outcomes

Primary

Measure	Time frame
Median effective dose;95% confidence limits;	—

Countries

China

Contacts

Public ContactWang Zhihua

Hainan General Hospital

13876012831@163.com+86 13876012831

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026